Literature DB >> 12439629

Treatment of heart failure with autologous skeletal myoblasts.

Juan C Chachques1, Barbara Cattadori, Jesus Herreros, Felipe Prosper, Jorge C Trainini, Didier Blanchard, Jean-Noël Fabiani, Alain Carpentier.   

Abstract

BACKGROUND: The management of patients with heart failure is a daily challenge for cardiologists and cardiac surgeons. Pharmacotherapy, atrio-biventricular resynchronization, myocardial revascularization, valve repair techniques, latissimus dorsi cardiomyopathy, acorn cardiac support device, heart transplantation and mechanical assist devices do not cover all the needs. The recent progress in cellular and molecular biology allows the development of new therapies for heart failure. TRANSPLANTATION OF AUTOLOGOUS CELLS: One of the most innovative consists in the transplantation of autologous ex-vivo expanded cells into the myocardium for heart muscle regeneration. This approach is called "cellular cardiomyoblasty".

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439629     DOI: 10.1007/s00059-002-2422-3

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  4 in total

Review 1.  Stem cells and cardiac repair: a critical analysis.

Authors:  Jonathan H Dinsmore; Nabil Dib
Journal:  J Cardiovasc Transl Res       Date:  2008-01-31       Impact factor: 4.132

2.  Targeting survival pathways to create infarct-spanning bridges of human embryonic stem cell-derived cardiomyocytes.

Authors:  Jun Luo; Matthew S Weaver; James E Dennis; Elizabeth Whalen; Michael A Laflamme; Margaret D Allen
Journal:  J Thorac Cardiovasc Surg       Date:  2014-07-24       Impact factor: 5.209

3.  Development of bioartificial myocardium using stem cells and nanobiotechnology templates.

Authors:  Juan Carlos Chachques
Journal:  Cardiol Res Pract       Date:  2010-12-29       Impact factor: 1.866

Review 4.  Key Success Factors for Regenerative Medicine in Acquired Heart Diseases.

Authors:  Philippe Hénon
Journal:  Stem Cell Rev Rep       Date:  2020-06       Impact factor: 5.739

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.